20,000 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Acquired by First Business Financial Services Inc.

First Business Financial Services Inc. bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 20,000 shares of the biotechnology company’s stock, valued at approximately $343,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vision Financial Markets LLC purchased a new stake in ADMA Biologics in the fourth quarter worth approximately $51,000. Arizona State Retirement System boosted its stake in shares of ADMA Biologics by 6.6% during the 4th quarter. Arizona State Retirement System now owns 67,581 shares of the biotechnology company’s stock worth $1,159,000 after acquiring an additional 4,170 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of ADMA Biologics by 52.8% during the 4th quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company’s stock worth $1,886,000 after acquiring an additional 38,002 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of ADMA Biologics by 1.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,440,294 shares of the biotechnology company’s stock worth $41,851,000 after acquiring an additional 38,761 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in shares of ADMA Biologics during the 4th quarter worth $141,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ADMA. HC Wainwright lifted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday. Finally, Raymond James lifted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

ADMA Biologics Stock Up 3.9 %

Shares of ADMA stock opened at $17.68 on Thursday. The company has a market capitalization of $4.18 billion, a price-to-earnings ratio of 63.14 and a beta of 0.75. ADMA Biologics, Inc. has a one year low of $5.71 and a one year high of $23.64. The company’s fifty day moving average price is $16.69 and its 200-day moving average price is $17.97. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.